These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34924354)

  • 21. Minimal change glomerulonephritis following the second dose of the Moderna COVID-19 vaccine.
    Park HJ; An WS; Rha SH; Kim SE; Lee SM
    QJM; 2022 Jul; 115(7):490-491. PubMed ID: 35380707
    [No Abstract]   [Full Text] [Related]  

  • 22. Cutaneous arteritis following mRNA-1273 Moderna COVID-19 vaccination.
    Ogawa T; Aitake U; Nomura T
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e399-e400. PubMed ID: 35066922
    [No Abstract]   [Full Text] [Related]  

  • 23. Delayed localized hypersensitivity reactions to COVID-19 mRNA vaccines: a 6-month retrospective study.
    Papadimitriou I; Bakirtzi K; Sotiriou E; Vakirlis E; Hatzibougias D; Ioannides D
    Clin Exp Dermatol; 2022 Jan; 47(1):157-158. PubMed ID: 34288056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moderna COVID-19 Vaccine Safe and Effective for Children 6 Months to 5 Years.
    Slomski A
    JAMA; 2022 Dec; 328(24):2388. PubMed ID: 36573976
    [No Abstract]   [Full Text] [Related]  

  • 25. The Polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients.
    Sellaturay P; Gurugama P; Harper V; Dymond T; Ewan P; Nasser S
    Clin Exp Allergy; 2022 Jan; 52(1):12-17. PubMed ID: 34822190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-limiting reactive disease mimicking polymyalgia rheumatica following Moderna COVID-19 vaccine.
    Nielsen AW; Hansen IT; Gormsen LC; Hauge EM; Keller KK
    Scand J Rheumatol; 2022 Sep; 51(5):411-413. PubMed ID: 35658808
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic Patients.
    Rojas-Pérez-Ezquerra P; Crespo Quirós J; Tornero Molina P; Baeza Ochoa de Ocáriz ML; Zubeldia Ortuño JM
    J Investig Allergol Clin Immunol; 2021 Apr; 31(2):180-181. PubMed ID: 33648905
    [No Abstract]   [Full Text] [Related]  

  • 28. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine.
    Holzworth A; Couchot P; Cruz-Knight W; Brucculeri M
    Kidney Int; 2021 Aug; 100(2):463-464. PubMed ID: 34048824
    [No Abstract]   [Full Text] [Related]  

  • 29. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
    Luxi N; Giovanazzi A; Capuano A; Crisafulli S; Cutroneo PM; Fantini MP; Ferrajolo C; Moretti U; Poluzzi E; Raschi E; Ravaldi C; Reno C; Tuccori M; Vannacci A; Zanoni G; Trifirò G;
    Drug Saf; 2021 Dec; 44(12):1247-1269. PubMed ID: 34739716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.
    Pitlick MM; Joshi AY; Gonzalez-Estrada A; Chiarella SE
    Allergy Asthma Proc; 2022 Jan; 43(1):40-43. PubMed ID: 34983709
    [No Abstract]   [Full Text] [Related]  

  • 31. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
    Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights.
    Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ
    Interdiscip Sci; 2021 Jun; 13(2):344-347. PubMed ID: 34021862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypersensitivity Lymphohistiocytic Myocarditis After Moderna mRNA-1273 Vaccine.
    Kounis NG; Mplani V; Kouni S; Plotas P; Koniari I
    Am J Clin Pathol; 2022 Oct; 158(4):555-556. PubMed ID: 35938624
    [No Abstract]   [Full Text] [Related]  

  • 34. Acute dizziness and mental alteration associated with Moderna COVID-19 vaccine: a case report.
    Pinzon RT; Haryono FK; Darmawan NE; Salikim MAM; Veronica V
    BMC Neurol; 2022 Aug; 22(1):322. PubMed ID: 36028809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ANCA glomerulonephritis after the Moderna COVID-19 vaccination.
    Sekar A; Campbell R; Tabbara J; Rastogi P
    Kidney Int; 2021 Aug; 100(2):473-474. PubMed ID: 34081948
    [No Abstract]   [Full Text] [Related]  

  • 36. Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy.
    Kudose S; Friedmann P; Albajrami O; D'Agati VD
    Kidney Int; 2021 Aug; 100(2):468-469. PubMed ID: 34146600
    [No Abstract]   [Full Text] [Related]  

  • 37. "Covid arm": Abnormal side effect after Moderna COVID-19 vaccine.
    Picone V; Martora F; Fabbrocini G; Marano L
    Dermatol Ther; 2022 Jan; 35(1):e15197. PubMed ID: 34750923
    [No Abstract]   [Full Text] [Related]  

  • 38. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.
    Wolfson AR; Robinson LB; Li L; McMahon AE; Cogan AS; Fu X; Wickner P; Samarakoon U; Saff RR; Blumenthal KG; Banerji A
    J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3308-3320.e3. PubMed ID: 34166844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022.
    Wallace M; Moulia D; Blain AE; Ricketts EK; Minhaj FS; Link-Gelles R; Curran KG; Hadler SC; Asif A; Godfrey M; Hall E; Fiore A; Meyer S; Su JR; Weintraub E; Oster ME; Shimabukuro TT; Campos-Outcalt D; Morgan RL; Bell BP; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(11):416-421. PubMed ID: 35298454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines.
    Caballero ML; Quirce S
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):92-93. PubMed ID: 33433387
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.